Cell therapy · Immune activation · developed by Enlivex Therapeutics
Allocetra-OTS is a cell-based therapy made of non-HLA-matched allogeneic peripheral blood mononuclear cells from a healthy donor, induced into an early apoptotic state and suspended in a DMSO-containing solution. The early apoptotic cells are engulfed by macrophages and immature dendritic cells, leading to immune modulation. It is studied in sepsis, community-acquired pneumonia, urinary tract infections, acute cholecystitis, acute cholangitis and intraabdominal infections.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04612413 | Phase 2 | Sepsis | Completed | ENLV |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Cholangitis AcuteCholecystitis, AcuteCommunity-acquired PneumoniaIntraabdominal InfectionsSepsisUrinary Tract Infections
Updated Oct 11, 2026. Something wrong or missing? Report it on the ENLV page.
See ENLV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ENLV catalysts and pipeline →